This argument is strengthened by the fact that the Bruton tyrosine kinase inhibitor ibrutinib is able to reduce secretion of CLL-EVs [11] and at the same time to increase efficacy of PD-1/PD-L1 blockade [73,74]. This evidence concerns the gene CD274 and B-cell chronic lymphocytic leukemia.